🔗 Share this article The Global Health Body Issues Alert Over Severe Scarcity of Weight-Loss Jabs Less than a tenth of patients who could benefit from weight-loss injections like Wegovy can access them, warns the World Health Organization as it issues its inaugural advice on the drugs. Given in excess of 1,000,000,000 people worldwide currently living with obesity, it is advocating for increased and just availability to these injectable treatments. Per projections, in excess of 2,000,000,000 could be obese by 2030 without intervention. "The latest guidance acknowledges that obesity is a chronic disease that can be treated with comprehensive and ongoing treatment," said its chief Tedros Adhanom Ghebreyesus. High costs, insufficient output, and supply-chain constraints are significant obstacles to universal availability to the injections that can assist patients in reducing significant body mass, notes the agency. Weight-Loss Drug Supply Crisis Even under the present best projected outlook, the supply of GLP-1 therapies would only suffice for approximately 100 million people – less than 10% of eligible patients, according to the WHO. The guideline calls on countries and companies to widen availability, via approaches such as voluntary licensing. A patent on a key compound – the core component of Novo Nordisk's Wegovy – is due to expire in several nations in 2026. The Way Weight-Loss Jabs Operate GLP-1 drugs mimick a biological compound to delay gastric emptying, suppress the appetite and enhance the sense of being full so users eat less. Patients commonly see weight reduction after several weeks of beginning the once-weekly jabs. Studies points to patients may put most of the weight back on after a year of stopping the drug, because their normal appetite return. To be overweight or obese raises your risk for developing medical conditions, like diabetes, cardiovascular issues, stroke, and some cancers. Obesity impacts individuals in countries worldwide and was responsible for 3.7 million fatalities worldwide in 2024, per the health agency.
Less than a tenth of patients who could benefit from weight-loss injections like Wegovy can access them, warns the World Health Organization as it issues its inaugural advice on the drugs. Given in excess of 1,000,000,000 people worldwide currently living with obesity, it is advocating for increased and just availability to these injectable treatments. Per projections, in excess of 2,000,000,000 could be obese by 2030 without intervention. "The latest guidance acknowledges that obesity is a chronic disease that can be treated with comprehensive and ongoing treatment," said its chief Tedros Adhanom Ghebreyesus. High costs, insufficient output, and supply-chain constraints are significant obstacles to universal availability to the injections that can assist patients in reducing significant body mass, notes the agency. Weight-Loss Drug Supply Crisis Even under the present best projected outlook, the supply of GLP-1 therapies would only suffice for approximately 100 million people – less than 10% of eligible patients, according to the WHO. The guideline calls on countries and companies to widen availability, via approaches such as voluntary licensing. A patent on a key compound – the core component of Novo Nordisk's Wegovy – is due to expire in several nations in 2026. The Way Weight-Loss Jabs Operate GLP-1 drugs mimick a biological compound to delay gastric emptying, suppress the appetite and enhance the sense of being full so users eat less. Patients commonly see weight reduction after several weeks of beginning the once-weekly jabs. Studies points to patients may put most of the weight back on after a year of stopping the drug, because their normal appetite return. To be overweight or obese raises your risk for developing medical conditions, like diabetes, cardiovascular issues, stroke, and some cancers. Obesity impacts individuals in countries worldwide and was responsible for 3.7 million fatalities worldwide in 2024, per the health agency.